RE:RE:RE:Trying to look at the positives..."But the driver at this point and the future for the next 12 months is to prove to the skeptical market they are growing at 15% and will see a large drop-off in spend starting soon, thus bringing more cash to the operating profit line. It will be those financial metrics that will move the share from the ridiculous $1 to something closer to intrinsic value for a company selling close to $100mil in products and moving to profitability on the bottom line next year."...
I haven't seen any plan to reduce cost for 2023 and we are already 3 month into the year.
According to the last Financial report, Dubuc said:
As we maintain a tight control on expenses, it will be our strategic imperative to become Adjusted EBITDA positive in order to deliver strong shareholder returns.
In 2022 main expenses were:
- Selling: $39m
- General & Admin. : $17m
- R&D: $37m
What is the plan to control expenses?
Nothing substancial has been said on this most important issue.
But for Levesque, the way to achieve the goal is:
..."We are also actively working towards the identification of potential in-licensing, co-promotion, or immediately accretive product acquisitions in order to accelerate this journey towards positive Adjusted EBITDA"...
With no plan to reduce selling, administrative or R&D budget, I expect they will drain what remains of shareholders value before the end of the year.